Press time:2021-05-20From:CR Pharma [Font:BigMediumSmall]
On the afternoon of May 20th, the signing ceremony of the cooperation agreement between China Resources Biopharmaceutical Co., Ltd. (hereafter referred to as CR Biopharmaceutical) and Hybio Pharmaceutical Co., Ltd. (hereafter referred to as Hybio Pharmaceutical) on the “Han’an Eptifibatide” was held in Shenzhen. According to the agreement, the two parties will conduct in-depth cooperation on the promotion and sales of the product. Eptifibatide is a key product used in antiplatelet therapy during percutaneous coronary intervention (PCI) for acute coronary syndromes.
Through the cooperation, CR Biopharmaceutical will bring more products aimed at cardiovascular and cerebrovascular diseases, and Hybio Pharmaceutical will also draw on CR Biopharmaceutical’s strength in quickly expanding its breadth and depth of the development of PCI product pipelines. In the future, the two parties will strive to build a multi-product and multi-dimensional cooperation model for cardio-cerebrovascular treatment through the development and introduction of more cardio-cerebrovascular products, and actively expand their cooperation in more fields.
CR Biopharmaceutical is a wholly-owned subsidiary and a platform for strategic management and resource allocation of biopharmaceuticals of China Resources Pharmaceutical Group Limited. At present, CR Biopharmaceutical has four subsidiaries, and its business covers the entire industry chain of biopharmaceutical R&D, production and sales. With modern production bases and high-level R&D centers with high-quality resources and strong capabilities, the company has launched products for cardiovascular, cerebrovascular, tumor and blood diseases.
Hybio Pharmaceutical is a leading domestic polypeptide drug manufacturer, and a National High-Tech Enterprise that specializes in the R&D, manufacture and sales of polypeptide drugs. The company has built a number of national technology platforms, such as the polypeptide drug production base under the national high-tech industrialization demonstration projects, and has undertaken more than 30 national-level major scientific and technological projects. It has broken through the technical bottleneck limiting the large-scale production of peptide drugs, and obtained more than 200 invention patents. Having been promoting the innovation and development of the peptide industry, the company has entered the Forbes List of China’s Potential Companies and the Top 500 Enterprises in Guangdong Province, and won the second prize of the State Technological Invention Award.
